Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Azithramycine
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Sher AA et al. | [Interactions in the system of copper ion-azalide (azithromycin)]. | 1994 Sep-Oct | Antibiot. Khimioter. | pmid:7695446 |
Iur'ev SIu et al. | [Azithromycin levels in the chorion tissue within the first three months of the pregnancy term]. | 2004 | Antibiot. Khimioter. | pmid:15850052 |
Iakovlev SV and Ukhin SA | [Azithromycin: general properties and regimen optimization based on pharmacokinetic and pharmacological parameters]. | 2003 | Antibiot. Khimioter. | pmid:12803047 |
Sidorenko SV | [Azithromycin--an antibiotic of the azalide group]. | 1993 | Antibiot. Khimioter. | pmid:8060181 |
Lopatkin NA et al. | [Use of azithromycin ("Sumamded") in the treatment of infectious-inflammatory diseases of the lower urinary tract and male genitalia]. | 1993 | Antibiot. Khimioter. | pmid:8060189 |
Euba B et al. | Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection. | 2015 | Antimicrob. Agents Chemother. | pmid:25712355 |
Liu P et al. | Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. | 2007 | Antimicrob. Agents Chemother. | pmid:17060516 |
Soltow SM and Brenner GM | Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. | 2007 | Antimicrob. Agents Chemother. | pmid:17060522 |
Beringer P et al. | Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. | 2005 | Antimicrob. Agents Chemother. | pmid:16304166 |
Ulrich M et al. | Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. | 2005 | Antimicrob. Agents Chemother. | pmid:16304181 |
Kohlhoff SA et al. | In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. | 2014 | Antimicrob. Agents Chemother. | pmid:25288086 |
Grinwis ME et al. | Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. | 2010 | Antimicrob. Agents Chemother. | pmid:20404127 |
Bosnar M et al. | Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. | 2005 | Antimicrob. Agents Chemother. | pmid:15917536 |
Singh S et al. | Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. | 2014 | Antimicrob. Agents Chemother. | pmid:24890593 |
Turcinov D et al. | Failure of azithromycin in treatment of Brill-Zinsser disease. | 2000 | Antimicrob. Agents Chemother. | pmid:10817744 |
Tsitsika A et al. | Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis. | 2000 | Antimicrob. Agents Chemother. | pmid:10817749 |
Bin XX et al. | Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10817751 |
Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
Kuo CC et al. | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8913488 |
Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
Pacifico L et al. | Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. | 1996 | Antimicrob. Agents Chemother. | pmid:8849215 |
Unemo M et al. | First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? | 2014 | Antimicrob. Agents Chemother. | pmid:24189248 |
Li H et al. | Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. | 2014 | Antimicrob. Agents Chemother. | pmid:24189261 |
Navarro G et al. | Image-based 384-well high-throughput screening method for the discovery of skyllamycins A to C as biofilm inhibitors and inducers of biofilm detachment in Pseudomonas aeruginosa. | 2014 | Antimicrob. Agents Chemother. | pmid:24295976 |
Blais J et al. | Inhibition of Toxoplasma gondii protein synthesis by azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8215287 |
Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
Edelstein PH and Edelstein MA | In vitro activity of azithromycin against clinical isolates of Legionella species. | 1991 | Antimicrob. Agents Chemother. | pmid:1849708 |
Kosowska K et al. | Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. | 2004 | Antimicrob. Agents Chemother. | pmid:15504829 |
Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
Biedenbach DJ et al. | Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. | 2010 | Antimicrob. Agents Chemother. | pmid:20625152 |
Piesman J et al. | Efficacy of an experimental azithromycin cream for prophylaxis of tick-transmitted lyme disease spirochete infection in a murine model. | 2014 | Antimicrob. Agents Chemother. | pmid:24165183 |
Chisholm SA et al. | High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. | 2010 | Antimicrob. Agents Chemother. | pmid:20585125 |
Deshpande D et al. | Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. | 2016 | Antimicrob. Agents Chemother. | pmid:26810646 |
Azoulay-Dupuis E et al. | Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. | 1991 | Antimicrob. Agents Chemother. | pmid:1656849 |
Chinh NT et al. | A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. | 2000 | Antimicrob. Agents Chemother. | pmid:10858343 |
Amacher DE et al. | Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. | 1991 | Antimicrob. Agents Chemother. | pmid:1656856 |
Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
Gunell M et al. | In vitro activity of azithromycin against nontyphoidal Salmonella enterica. | 2010 | Antimicrob. Agents Chemother. | pmid:20498312 |
Pfefferkorn ER and Borotz SE | Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8141576 |
Pene Dumitrescu T et al. | Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. | 2013 | Antimicrob. Agents Chemother. | pmid:23629714 |
Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
Caronzolo D et al. | Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15561871 |
Carter G et al. | A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. | 2004 | Antimicrob. Agents Chemother. | pmid:15561879 |
Sjölund Karlsson M et al. | Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States. | 2013 | Antimicrob. Agents Chemother. | pmid:23274665 |
Dreses-Werringloer U et al. | Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. | 2001 | Antimicrob. Agents Chemother. | pmid:11600348 |
Tateda K et al. | Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. | 2001 | Antimicrob. Agents Chemother. | pmid:11353657 |
Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |
Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
Akova M et al. | In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. | 1999 | Antimicrob. Agents Chemother. | pmid:10223958 |
Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |